BioLife Solutions: Cross-Selling and CGT Tailwinds Power Another Strong Quarter
Revenue up 25%, guidance reaffirmed, and a clear path to resolve the bag yield drag
BLFS · Earnings Call · 2026-05-08
Strong Start, Strong Guidance
BioLife Solutions kicked off 2026 with a 25% revenue increase to $27.5 million, while adjusted EBITDA reached $6.2 million (22% of revenue). The company reaffirmed its full-year guidance of $112.5–115 million in revenue (17–20% growth) and reiterated its expectation of positive GAAP net income for the first time in years. Management's message is consistent: a simplified business focused on recurring, high-margin revenue is delivering operating leverage. “BPM represents over 85% of total revenue and continues to benefit from broad adoption across both commercial therapies and clinical pipelines where we maintain a dominant market share.” — Roderick de Greef, Chief Executive Officer and Chairman of the Board · 2026-05-08 The core end market — cell and gene therapy (CGT) — continues to expand. Management cited large autoimmune indications, allogeneic therapies, and a more stable funding environment as tailwinds. This is reflected in the strong commercial traction: commercial therapy customers now represent roughly half of BPM revenue, and the pipeline of 17 approved therapies plus 9 anticipated approvals provides good visibility.Cross-Selling and the Bag Yield Resolution
Beyond media, the cross-selling story is gaining traction. The company is leveraging its dominance in biopreservation media to attach other tools: CellSeal vials, hPL, CryoCase, and the automated fill system. The potential revenue per dose could increase 2–3× with additional products. PanTHERA's launch remains on track for Q4, and the rigid container (RCC) is being developed to replace bags in the front-end shipping process. The key operational priority is resolving the bag yield issue, which has been dragging gross margins. Management expects a solution via a 90-day customer notification and inventory burn-through, with margin flow-through in Q4 2026 or Q1 2027. “We're on track for the same sort of timing as we had laid out in the last phone call we had... we would expect to be able to see some flow-through of enhanced margin either Q4 or Q1 of '27.” — Roderick de Greef, Chief Executive Officer and Chairman of the Board · 2026-05-08 The financials underscore the operational progress. Revenue has rebounded strongly from the 2022 trough, and gross margin is back to mid-60s. The company's effective net cash remains substantial at $109 million, providing flexibility for M&A and strategic investments. Total revenue reached $28 million in Q1 2026, up 15% year-over-year and 46% sequentially, reflecting the recovery in CGT demand.CGT Tailwinds and Investor Momentum
The broader CGT landscape is evolving favorably. Management noted that data emerging in allogeneic cell therapies could unlock multibillion-dollar opportunities, and the recent nearly $8 billion acquisition of Arcellx by Gilead underscores strategic interest in the space. The company's own pipeline remains deep, with more than 250 commercially sponsored clinical trials using its solutions.Investors have taken notice: the stock has climbed nearly 88% over the past 90 days, reflecting confidence in the growth algorithm and the resolution of the yield issue. Funding dynamics are also stabilizing, with management downplaying the impact of biotech funding on their business. “The bulk of the revenue, certainly the revenue growth is coming from well-capitalized firms.” — Roderick de Greef, Chief Executive Officer and Chairman of the Board · 2026-05-08 Prior calls laid the groundwork. In February, management guided that commercial customers would reach 50–55% of revenue, a target the current quarter is tracking toward. The bag yield remediation plan was also outlined then, reinforcing a consistent narrative. “We would expect our commercial customers to be somewhere between 50%-55% in 2026.” — Roderick de Greef, CEO · 2026-02-26 “We're expecting to increase prices in '26 between 4% and 6% depending on the SKU.” — Roderick de Greef, CEO and Chairman of the Board · 2025-11-06 With a clear operational plan, a dominant market position in media, and a cross-selling opportunity that compounds revenue per dose, BioLife Solutions is positioned for durable growth. The temporary bag yield drag is a known variable, and management's disciplined execution suggests the path to margin expansion is well-defined.As these therapies evolve and care settings shift, whether into outpatient and community settings or toward off-the-shelf approaches, this is expected to support sustained demand for robust, high-quality and trusted cell processing tools, biopreservation media and packaging solutions, areas where BioLife is well positioned.